Skip to main content
. 2019 Feb 4;98(4):823–831. doi: 10.1007/s00277-019-03605-1

Fig. 3.

Fig. 3

a Kaplan–Meier product estimate of the cumulative probability of progression-free survival (PFS) in patients who had response (n = 23) or no response to etoposide (n = 17). b Kaplan–Meier product estimate of the cumulative probability of overall survival (OS) in patients who had response (n = 23) or no response to etoposide (n = 17)